October 24, 2018
Ricardo Dolmetsch, Global Head of Neuroscience, Novartis Institutes for Biomedical Research As Novartis gears up for the filing of AVXS-101, a gene therapy it snapped up with its AveXis buyout earlier this year, the company’s global head for neuroscience aired...read more